CML: outcomes in a large real-world cohort

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Treatment responses were favorable in a cohort of real-world patients with chronic myeloid leukemia (CML) with superior outcomes in those who received a second-generation tyrosine kinase inhibitor (TKI) as first-line therapy.

Why this matters

  • Data is scant regarding real-wo...